Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Business Update and Cancellation of Share Buyback

10/18/2021 | 02:01am EST

Arix Bioscience PLC (ARIX) Business Update and Cancellation of Share Buyback 18-Oct-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Business Update and Cancellation of Share Buyback

LONDON, 18 October 2021: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces a number of developments.

Over the past six months Arix has worked to position the Company for the future which has involved a number of strategic actions. The Board has been strengthened, most recently with the addition of Sir Michael Bunbury as Senior Independent Director, whilst the Investment Team has been expanded. This started with Mark Chin re-joining Arix in July 2021. Mark had been instrumental in driving much of the current portfolio, including VelosBio which was acquired by Merck for USD2.75 billion generating gross proceeds to Arix of GBP138.5 million and a 12.5x return on the original investment. In the three months since re-joining Arix, Mark has already led a new investment, GBP8 million into Disc Medicine, which is developing novel therapies to treat serious and debilitating haematological disorders.

Today, Arix is pleased to announce that David Cristina, PhD, has also joined Arix as a secondee from Fosun International where he was Head of Fosun's European Healthcare Investment Team. David has 15 years' experience in early stage investment and venture-building and is an expert in the ageing research field. As part of Arix's strategic relationship with Fosun International, David will provide additional capacity and expertise to the Investment Team.

Meanwhile Arix's portfolio has continued to mature. In addition to the new investment into Disc Medicine, existing portfolio company Pyxis Oncology, which is developing next-generation therapeutics to target difficult-to-treat cancers, listed on Nasdaq Global Market on 8 October 2021. Portfolio company Aura Biosciences, which is developing a novel treatment for primary choroidal melanoma, has also filed its intention to IPO on Nasdaq.

Arix has continued to see a strong pipeline of promising investment opportunities and with the expanded Investment Team it is confident that it can continue to profitably deploy the cash generated from recent realisations.

The Board has therefore decided to cease its share buyback programme, announced on 15 March 2021, with immediate effect. The cancellation of the share buyback programme will enable Arix to pursue greater value creation through investment into the most innovative biotech companies. It demonstrates Arix's commitment to creating and delivering value for all stakeholders and the Board's confidence in the business. During the programme Arix has spent GBP11.5 million and bought back 6,429,853 shares, representing 4.7% of its issued share capital prior to starting the programme. The average price paid was GBP1.79 per share, compared to the last reported NAV per share of GBP2.14.

Robert Lyne, Chief Executive Officer of Arix, said: "I am delighted to welcome David to the Investment Team. He brings a wealth of international experience and a successful track record of supporting exciting biotech companies. We continue to build our team by adding new talent to deploy investment capital from the realisations of our portfolio and I am pleased that we are seeing numerous exciting investment opportunities in the US and Europe. Ceasing our share buyback programme early demonstrates our confidence in the Investment Team, our pipeline and our ability to deploy capital profitably and to generate superior risk-adjusted returns."



For more information on Arix, please contact:

Arix Bioscience plc +44 (0) 20 7290 1050 ir@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Manel Mateus +44 (0)20 8078 4357 optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com


ISIN:           GB00BD045071 
Category Code:  MSCH 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   124516 
EQS News ID:    1241266 
End of Announcement  EQS News Service 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1241266&application_name=news

(END) Dow Jones Newswires

October 18, 2021 02:00 ET (06:00 GMT)

11/08Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
10/29Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
10/18ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
10/18Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
10/18Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
10/12ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
10/08ARIX BIOSCIENCE : Investee Pyxis Oncology Raises $167.2 Million in US IPO
10/06FTSE 100 Closes Down on Fears of Rising Consumer Costs
10/06FTSE Drops, Sterling Expected to Gain on Prospect of Rate Rise
10/06ARIX BIOSCIENCE : Makes Interim CEO Permanent
More news
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 176 M 176 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 152 M 201 M 201 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 72,0%
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | ARIX | GB00BD045071 | MarketScreener
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 122,50 GBX
Average target price 256,00 GBX
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INVESTOR AB (PUBL)54.38%75 393
HAL TRUST23.45%13 934